RxDoctor Payments Data

Marti Willey

Nurse Practitioner · Encinitas, CANPI 1144574062

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $25,041 of the $36,816 with a category attached, or 68.0%. 60 manufacturers reported payments, led by Gilead at 28.4% of the total. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,816in general payments, 2019–2025

Across 1,041 payments — averaging $35.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$10K
  • Novartis$4K
  • Johnson & Johnson$3K
  • Merck$2K
  • Pfizer$1K
  • AstraZeneca$1K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$6,52318%
  • Travel & lodging$1,8175%
  • Food & beverage$25,04168%
  • Education$1,0393%
  • Other$2,3977%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead(2 entities)83$10,474
Novartis78$3,521
Johnson & Johnson(2 entities)60$2,638
Merck70$1,501
Pfizer66$1,313
AstraZeneca(2 entities)50$1,226
Sanofi35$1,157
GSK30$878
E.r. Squibb & Sons, L.L.C.31$859
AbbVie30$815
Bristol Myers Squibb38$814
Eisai Inc.20$632
Pharmacyclics LLC, An Abbvie Company24$561
Incyte Corporation21$527
Amgen16$497
Takeda Pharmaceuticals U.S.A., Inc.22$485
Blueprint Medicines Corporation12$481
Daiichi Sankyo Inc.23$447
Bayer22$439
Beigene USA, Inc.17$379
Sobi, Inc13$364
Seagen Inc.18$362
Genentech USA, Inc.15$356
Regeneron Healthcare Solutions, Inc.13$334
Ipsen Biopharmaceuticals, Inc14$312
Array Biopharma Inc19$304
Puma Biotechnology, Inc.12$293
Deciphera Pharmaceuticals Inc.9$281
Pharmaessentia USA Corporation8$258
AVEO Pharmaceuticals, Inc.6$234
EMD Serono, Inc.10$215
Astellas Pharma US Inc7$207
Mirati Therapeutics, Inc.8$202
Rigel Pharmaceuticals, Inc.7$186
Genmab U.S., Inc.7$182
Caris MPI, Inc.2$160
Boehringer Ingelheim6$159
Coherus Oncology, Inc.7$154
ADC Therapeutics America, Inc.5$144
Iovance Biotherapeutics, Inc.4$134
Karyopharm Therapeutics Inc.5$129
Beone Medicines USA, Inc.5$120
Agios Pharmaceuticals, Inc.5$119
Taiho Oncology, Inc.4$108
Geron Corporation4$108
Epizyme, Inc.2$104
Lilly USA, LLC6$104
Exelixis Inc.4$102
Acrotech Biopharma Inc.5$89
Tersera Therapeutics LLC3$86
Cumberland Pharmaceuticals, Inc.5$82
Tactile Systems Technology Inc4$79
Verity Pharmaceuticals Inc.3$78
Octapharma USA, Inc.4$75
Fresenius Kabi USA, LLC3$71
Servier Pharmaceuticals LLC3$70
Jazz Pharmaceuticals Inc.3$63
Menarini Silicon Biosystems, Inc.3$59
Edwards Lifesciences1$58
Accord Healthcare, Inc.3$57

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,816 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$164,451
Medicare patients
186
Services billed
16,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate12$205,267
KisqaliRibociclib Succinate11$189,483
EliquisApixaban17$15,778
Exemestane35$5,972
Anastrozole119$2,459
Ondansetron OdtOndansetron74$1,356
Dexamethasone28$1,274
Prochlorperazine Maleate83$858
Megestrol Acetate17$743
Letrozole31$608
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$516
Acyclovir23$507
Tamoxifen Citrate23$506
Morphine Sulfate ErMorphine Sulfate12$392
Hydroxyurea15$359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$527$205,26712 claims
NovartisKisqali$3,521$189,48311 claims
PfizerEliquis$1,313$15,77817 claims
Lilly USA, LLCOlanzapine$104$24111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →